A citation-based method for searching scientific literature

Frederick G Hayden, Norio Sugaya, Nobuo Hirotsu, Nelson Lee, Menno D de Jong, Aeron C Hurt, Tadashi Ishida, Hisakuni Sekino, Kota Yamada, Simon Portsmouth, Keiko Kawaguchi, Takao Shishido, Masatsugu Arai, Kenji Tsuchiya, Takeki Uehara, Akira Watanabe. N Engl J Med 2018
Times Cited: 317







List of co-cited articles
568 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
Michael G Ison, Simon Portsmouth, Yuki Yoshida, Takao Shishido, Melissa Mitchener, Kenji Tsuchiya, Takeki Uehara, Frederick G Hayden. Lancet Infect Dis 2020
46
67

Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.
Shinya Omoto, Valentina Speranzini, Takashi Hashimoto, Takeshi Noshi, Hiroto Yamaguchi, Makoto Kawai, Keiko Kawaguchi, Takeki Uehara, Takao Shishido, Akira Naito,[...]. Sci Rep 2018
166
29

In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
Takeshi Noshi, Mitsutaka Kitano, Keiichi Taniguchi, Atsuko Yamamoto, Shinya Omoto, Keiko Baba, Takashi Hashimoto, Kayo Ishida, Yukihiro Kushima, Kazunari Hattori,[...]. Antiviral Res 2018
125
28

Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes.
Nobuo Hirotsu, Hiroki Sakaguchi, Chisako Sato, Toru Ishibashi, Keiko Baba, Shinya Omoto, Takao Shishido, Kenji Tsuchiya, Frederick G Hayden, Takeki Uehara,[...]. Clin Infect Dis 2020
47
51

Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
Takeki Uehara, Frederick G Hayden, Keiko Kawaguchi, Shinya Omoto, Aeron C Hurt, Menno D De Jong, Nobuo Hirotsu, Norio Sugaya, Nelson Lee, Keiko Baba,[...]. J Infect Dis 2020
63
36

Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019.
Emi Takashita, Masataka Ichikawa, Hiroko Morita, Rie Ogawa, Seiichiro Fujisaki, Masayuki Shirakura, Hideka Miura, Kazuya Nakamura, Noriko Kishida, Tomoko Kuwahara,[...]. Emerg Infect Dis 2019
49
38

Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Emi Takashita, Rod S Daniels, Seiichiro Fujisaki, Vicki Gregory, Larisa V Gubareva, Weiijuan Huang, Aeron C Hurt, Angie Lackenby, Ha T Nguyen, Dmitriy Pereyaslov,[...]. Antiviral Res 2020
33
48

Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.
Hideyuki Ikematsu, Frederick G Hayden, Keiko Kawaguchi, Masahiro Kinoshita, Menno D de Jong, Nelson Lee, Satoru Takashima, Takeshi Noshi, Kenji Tsuchiya, Takeki Uehara. N Engl J Med 2020
29
55

Influenza virus polymerase inhibitors in clinical development.
Frederick G Hayden, Nahoko Shindo. Curr Opin Infect Dis 2019
85
16

Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.
Larisa V Gubareva, Vasiliy P Mishin, Mira C Patel, Anton Chesnokov, Ha T Nguyen, Juan De La Cruz, Sarah Spencer, Angela P Campbell, Mallory Sinner, Heather Reid,[...]. Euro Surveill 2019
48
29

The mechanism of resistance to favipiravir in influenza.
Daniel H Goldhill, Aartjan J W Te Velthuis, Robert A Fletcher, Pinky Langat, Maria Zambon, Angie Lackenby, Wendy S Barclay. Proc Natl Acad Sci U S A 2018
122
14

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1.
Vasiliy P Mishin, Mira C Patel, Anton Chesnokov, Juan De La Cruz, Ha T Nguyen, Lori Lollis, Erin Hodges, Yunho Jang, John Barnes, Timothy Uyeki,[...]. Emerg Infect Dis 2019
27
51

Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2).
Jeffrey Baker, Stanley L Block, Balpreet Matharu, Laura Burleigh Macutkiewicz, Steffen Wildum, Sophie Dimonaco, Neil Collinson, Barry Clinch, Pedro A Piedra. Pediatr Infect Dis J 2020
18
77

Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019.
Emi Takashita, Chiharu Kawakami, Rie Ogawa, Hiroko Morita, Seiichiro Fujisaki, Masayuki Shirakura, Hideka Miura, Kazuya Nakamura, Noriko Kishida, Tomoko Kuwahara,[...]. Euro Surveill 2019
53
24

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.
Timothy M Uyeki, Henry H Bernstein, John S Bradley, Janet A Englund, Thomas M File, Alicia M Fry, Stefan Gravenstein, Frederick G Hayden, Scott A Harper, Jon Mark Hirshon,[...]. Clin Infect Dis 2019
174
12

Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets.
Masaki Imai, Makoto Yamashita, Yuko Sakai-Tagawa, Kiyoko Iwatsuki-Horimoto, Maki Kiso, Jurika Murakami, Atsuhiro Yasuhara, Kosuke Takada, Mutsumi Ito, Noriko Nakajima,[...]. Nat Microbiol 2020
42
28

Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.
Jeremy C Jones, Philippe Noriel Q Pascua, Thomas P Fabrizio, Bindumadhav M Marathe, Patrick Seiler, Subrata Barman, Richard J Webby, Robert G Webster, Elena A Govorkova. Proc Natl Acad Sci U S A 2020
15
73

Drug resistance in influenza A virus: the epidemiology and management.
Mazhar Hussain, Henry D Galvin, Tatt Y Haw, Ashley N Nutsford, Matloob Husain. Infect Drug Resist 2017
169
10

Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study.
Bruno Lina, Charles Boucher, Albert Osterhaus, Arnold S Monto, Martin Schutten, Richard J Whitley, Jonathan S Nguyen-Van-Tam. Influenza Other Respir Viruses 2018
48
20

Baloxavir: First Global Approval.
Young-A Heo. Drugs 2018
69
14

Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.
Michael P Clark, Mark W Ledeboer, Ioana Davies, Randal A Byrn, Steven M Jones, Emanuele Perola, Alice Tsai, Marc Jacobs, Kwame Nti-Addae, Upul K Bandarage,[...]. J Med Chem 2014
118
10

Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.
Emi Takashita, Chiharu Kawakami, Hiroko Morita, Rie Ogawa, Seiichiro Fujisaki, Masayuki Shirakura, Hideka Miura, Kazuya Nakamura, Noriko Kishida, Tomoko Kuwahara,[...]. Euro Surveill 2019
49
20

Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.
Jennifer L McKimm-Breschkin. Influenza Other Respir Viruses 2013
182
10

Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
Stella G Muthuri, Sudhir Venkatesan, Puja R Myles, Jo Leonardi-Bee, Tarig S A Al Khuwaitir, Adbullah Al Mamun, Ashish P Anovadiya, Eduardo Azziz-Baumgartner, Clarisa Báez, Matteo Bassetti,[...]. Lancet Respir Med 2014
371
10

Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir.
Anton Chesnokov, Mira C Patel, Vasiliy P Mishin, Juan A De La Cruz, Lori Lollis, Ha T Nguyen, Vivien Dugan, David E Wentworth, Larisa V Gubareva. J Infect Dis 2020
21
47

Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.
Timothy M Uyeki, Henry H Bernstein, John S Bradley, Janet A Englund, Thomas M File, Alicia M Fry, Stefan Gravenstein, Frederick G Hayden, Scott A Harper, Jon Mark Hirshon,[...]. Clin Infect Dis 2019
145
10

Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
Liva Checkmahomed, Zeineb M'hamdi, Julie Carbonneau, Marie-Christine Venable, Mariana Baz, Yacine Abed, Guy Boivin. J Infect Dis 2020
24
41

Estimates of global seasonal influenza-associated respiratory mortality: a modelling study.
A Danielle Iuliano, Katherine M Roguski, Howard H Chang, David J Muscatello, Rakhee Palekar, Stefano Tempia, Cheryl Cohen, Jon Michael Gran, Dena Schanzer, Benjamin J Cowling,[...]. Lancet 2018
833
10

Neuraminidase inhibitors for influenza.
Anne Moscona. N Engl J Med 2005
701
9

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
J J Treanor, F G Hayden, P S Vrooman, R Barbarash, R Bettis, D Riff, S Singh, N Kinnersley, P Ward, R G Mills. JAMA 2000
719
9

Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial.
Robert W Finberg, Riin Lanno, David Anderson, Roman Fleischhackl, Wilbert van Duijnhoven, Robert S Kauffman, Teddy Kosoglou, Johan Vingerhoets, Lorant Leopold. J Infect Dis 2019
43
20

Favipiravir (T-705), a novel viral RNA polymerase inhibitor.
Yousuke Furuta, Brian B Gowen, Kazumi Takahashi, Kimiyasu Shiraki, Donald F Smee, Dale L Barnard. Antiviral Res 2013
485
9

T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro.
Tatiana Baranovich, Sook-San Wong, Jianling Armstrong, Henju Marjuki, Richard J Webby, Robert G Webster, Elena A Govorkova. J Virol 2013
194
9

Influenza and antiviral resistance: an overview.
Temi Lampejo. Eur J Clin Microbiol Infect Dis 2020
36
25

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.
Yousuke Furuta, Takashi Komeno, Takaaki Nakamura. Proc Jpn Acad Ser B Phys Biol Sci 2017
381
8

Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study.
Akira Watanabe, Tadashi Ishida, Nobuo Hirotsu, Keiko Kawaguchi, Toru Ishibashi, Takao Shishido, Chisako Sato, Simon Portsmouth, Kenji Tsuchiya, Takeki Uehara. Antiviral Res 2019
16
50

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.
Angie Lackenby, Terry G Besselaar, Rod S Daniels, Alicia Fry, Vicki Gregory, Larisa V Gubareva, Weijuan Huang, Aeron C Hurt, Sook-Kwan Leang, Raphael T C Lee,[...]. Antiviral Res 2018
57
14

Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials.
Joanna Dobson, Richard J Whitley, Stuart Pocock, Arnold S Monto. Lancet 2015
281
8

Baloxavir marboxil: the new influenza drug on the market.
Ryan O'Hanlon, Megan L Shaw. Curr Opin Virol 2019
50
16

Antivirals targeting the polymerase complex of influenza viruses.
Edin J Mifsud, Frederick G Hayden, Aeron C Hurt. Antiviral Res 2019
54
14

Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.
Randal A Byrn, Steven M Jones, Hamilton B Bennett, Chris Bral, Michael P Clark, Marc D Jacobs, Ann D Kwong, Mark W Ledeboer, Joshua R Leeman, Colleen F McNeil,[...]. Antimicrob Agents Chemother 2015
110
8

Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia.
A C Hurt, K Hardie, N J Wilson, Y M Deng, M Osbourn, S K Leang, R T C Lee, P Iannello, N Gehrig, R Shaw,[...]. J Infect Dis 2012
105
7

Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.
Jose M Trevejo, Mohammed Asmal, Johan Vingerhoets, Ramon Polo, Sarah Robertson, Ying Jiang, Tara L Kieffer, Lorant Leopold. Antivir Ther 2018
30
23

Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
Keita Fukao, Takeshi Noshi, Atsuko Yamamoto, Mitsutaka Kitano, Yoshinori Ando, Takahiro Noda, Kaoru Baba, Kazumi Matsumoto, Naoko Higuchi, Minoru Ikeda,[...]. J Antimicrob Chemother 2019
39
17

Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil.
Emi Takashita, Hiroko Morita, Rie Ogawa, Kazuya Nakamura, Seiichiro Fujisaki, Masayuki Shirakura, Tomoko Kuwahara, Noriko Kishida, Shinji Watanabe, Takato Odagiri. Front Microbiol 2018
45
15

Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.
Paulina Koszalka, Danielle Tilmanis, Merryn Roe, Dhanasekaran Vijaykrishna, Aeron C Hurt. Antiviral Res 2019
28
25


Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission.
Leo Yi Yang Lee, Jie Zhou, Rebecca Frise, Daniel H Goldhill, Paulina Koszalka, Edin J Mifsud, Kaoru Baba, Takahiro Noda, Yoshinori Ando, Kenji Sato,[...]. PLoS Pathog 2020
12
58

Influenza.
Florian Krammer, Gavin J D Smith, Ron A M Fouchier, Malik Peiris, Katherine Kedzierska, Peter C Doherty, Peter Palese, Megan L Shaw, John Treanor, Robert G Webster,[...]. Nat Rev Dis Primers 2018
276
7



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.